Rapidly Resolving Nonalcoholic Marchiafava-Bignami Disease in the Setting of Malnourishment After Gastric Bypass Surgery

Moshe Bachar, MD1, Eduard Fatakhov, MD1, Christopher Banerjee, MD, MPH1,*, and Nathan Todnem, MD1

Abstract

Objectives. We describe a rare case of nonalcoholic Marchiafava-Bignami disease (MBD) in the setting of malnourishment after gastric bypass. Methods. A 44-year-old nonalcoholic Caucasian woman with malnutrition after gastric bypass presented with 2 weeks of weakness. The patient acutely became stuporous. Brain magnetic resonance imaging showed lesions in the corpus callosum and internal capsules consistent with MBD. After 10 days of treatment, the patient had resolution of her encephalopathy with return to baseline mental function, with radiological improvement. Results. MBD is a rare neurological disorder seen in alcoholics and can rapidly progress to coma or death. Our patient was successfully treated with a regimen typically used in alcoholics. We discuss the relevant literature supporting this regimen. Conclusions. This case demonstrates that since the pathophysiological etiology of the disease is malnutrition, MBD patients can be effectively treated with this regimen regardless of the underlying cause.

Keywords
Marchiafava-Bignami disease, gastric bypass, malnourishment

Introduction

Marchiafava-Bignami disease (MBD) is a rare disorder strongly associated with chronic alcohol consumption that is characterized by severe neurologic symptoms including dysarthria, impaired or fluctuating consciousness, and quadriparesis and is associated with other neuropsychiatric disorders. This disease was named after Marchiafava and Bignami, who described the symptoms in Italian men who consumed large amounts of Chianti wine.1 Heinrich et al2 demonstrated that the most common symptoms of MBD included cognitive impairment (seen in all patients), disconnection syndromes, gegenhalten, dysarthria, pyramidal tract symptoms, and seizures. Moreover, males averaging 40 to 60 years of age were most often hospitalized with MBD. With the advent of widely available neuroradiological imaging, the mortality of this disease has decreased from a typically lethal course to about 8%.3,4 In this report, we present a patient with clinically severe MBD with complete symptom resolution following treatment. We also review the currently accepted standards of treatment based on previously reported cases.

Case Report

A 44-year-old Caucasian woman presented to the emergency room with a 2-week history of anorexia, progressive weakness, and difficulty walking. She had a past medical history of obesity, schizophrenia, and bipolar disorder. Her past surgical history was significant for Roux-en-Y gastric bypass surgery 23 years ago. The patient was functionally independent 2 months prior to admission with acute deterioration in the 2 weeks preceding the admission.

Initial examination revealed a markedly pale and malnourished woman with a body mass index of 14.9 who had lost 8 kg in the preceding 4 months. She had tachycardia with mild epigastric tenderness. She was awake and oriented to person, place, and time. Her pupils were equal, round,
reactive to light, and her cranial nerve function was normal. Her strength was 4/5 in bilateral upper extremities and 3/5 in bilateral lower extremities, with preserved sensation. Normal reflexes including unsustained ankle clonus were present bilaterally. Laboratory tests on admission revealed the following: white blood cell count 4800/mm3 (normal); hemoglobin 10.1 g/dL (mildly low); mean corpuscular volume 111 fL (mildly high); blood glucose 106 mg/dL (normal); albumin 2.2 g/dL (low); prothrombin time 11.3 seconds (normal); total bilirubin 2.3 mg/dL (normal-high); alkaline phosphatase 201 U/L (normal); aspartate aminotransferase 175 U/L (high); alanine aminotransferase 65 U/L (high); ammonia 98 µmol/L (high); folate 16 ng/mL (normal); and vitamin B12 1745 pg/mL (normal). Hepatic ultrasound showed a moderately fatty liver without mass or cirrhosis. Initial therapy consisted of 100 mg thiamine, 1 mg folic acid, multivitamins, and magnesium sulfate. The patient’s home medications, quetiapine and clonazepam, were held. A nasojejunal tube was placed and feeding was started slowly.

The day after admission the patient abruptly became nonverbal and responsive only to pain. She also developed flaccid paralysis of both arms and persistent rhythmic jerking of her legs and feet. These findings are not typical of Wernike or Wernike-Korsakoff syndromes. Refeeding syndrome (with encephalopathic/neurologic manifestations of electrolyte abnormalities) was considered; however, her repeat serum laboratory tests were unremarkable (including sodium of 140, glucose 80, and phosphate 2.9). Additionally, 1-hour electroencephalogram was negative for seizures. Cerebrospinal fluid analysis was unremarkable, ruling out infectious and aseptic meningitis. Brain magnetic resonance imaging (MRI) revealed lesions involving the splenium of the corpus callosum and the posterior limb of both internal capsules (Figures 1 and 2). While extrapontine myelinolysis and hypoglycemic encephalopathy were considered, the aforementioned laboratory values preclude their diagnosis. Atherosclerotic ischemic stroke comes to mind; however, it is inconsistent with this pattern of diffusion restriction. The pattern is most consistent with type B MBD (focal corpus callosum lesions, as opposed to type A with complete callosal involvement), and the patient’s clinical findings match those of MBD. The patient was started on intravenous (IV) methylprednisolone 1 g IV every 24 hours for 5 doses; and 2 doses of cyanocobalamin 1 g intramuscular. The dosing regimen for thiamine and folate were chosen partly from the doses used in alcoholics to prevent Wernicke-Korsakoff syndrome.4,5 Other B vitamins including pyridoxine and cyanocobalamin have been studied as well, though there is no standard dose. We made the clinical decision to use all 4 given the patient’s known malnutrition and very low negative effects of vitamin administration. The patient was continued on thiamine 100 mg PO daily and folic acid 1 mg PO daily on clinical resolution of the acute disease process.

The decision was made to use corticosteroids as well. A recent review of literature of 153 MBD (7% which were non-alcoholic) suggests that, while thiamine clearly improves outcomes, steroids did not independently improve outcomes.6 As our patient resolved, the treatment course was stopped after 5 doses. Had the patient had edema on her MRIs, resolving edema could have been attributable to steroids; in this absence, it is unclear whether steroids independent of thiamine/vitamins contributed to our patient’s neurological improvement. Additionally, our patient developed a gastrointestinal bleed in the setting of previous bariatric surgery (though correlation is unknown). Steroids are
Figure 2. Axial diffusion weighted imaging showing lesions in the splenium (white arrow) and posterior limb of both internal capsules (black arrows). Below are the repeat axial diffusion weighted images obtained 15 days later showing resolution of splenium and internal capsule abnormalities.

Table 1. An Outline of the Treatment Duration, Dosage, and Medication for Our Patient.

| Day  | Thiamine       | Pyridoxine (Vitamin B₆) | Methylprednisolone | Cyanocobalamin (Vitamin B₁₂) | Folic Acid |
|------|----------------|-------------------------|--------------------|-----------------------------|------------|
| 1/8-14 | 100 mg PO q24h |                         |                    |                             |            |
| 1/15  | 100 mg in 50 mL NS IV x 1 and 100 mg PO q24h |                         |                    |                             |            |
| 1/16  | 500 mg in 100 mL NS IV q8h and 100 mg PO q24h |                         | 1 g IM x 1         |                             |            |
| 1/17  | 500 mg in 100 mL NS IV q8h and 100 mg PO q24h |                         |                    |                             |            |
| 1/18  | 500 mg in 100 mL NS IV q24h |                         |                    |                             |            |
| 1/19  | 500 mg in 100 mL NS IV q24h |                         |                    |                             |            |
| 1/20  | 500 mg in 100 mL NS IV q24h |                         |                    |                             |            |
| 1/21  | 500 mg in 100 mL NS IV q24h |                         |                    |                             |            |
| 1/22  | 500 mg in 100 mL NS IV q24h |                         |                    |                             |            |
| 1/23  | 100 mg in 50 mL NS IV q24h |                         |                    |                             |            |
| 1/24  | 100 mg in 50 mL NS IV q24h |                         |                    |                             |            |
| 1/25  | 100 mg in 50 mL NS IV q24h |                         |                    |                             |            |
| 1/26  | 100 mg in 50 mL NS IV q24h |                         |                    |                             |            |

Abbreviations: NS, normal saline; IV, intravenous; IM, intramuscular.
known precipitators of gastrointestinal bleeds, thus caution with the use of steroids in MBD patients is endorsed given the literature showing that steroids do not independently improve outcomes in MBD.

**Conclusion**

This case documents the diagnosis of a clinically severe MBD in a nonalcoholic with complete symptom resolution following treatment with thiamine, steroids, and other vitamins. This case also demonstrates that prompt recognition and treatment of this disease may prevent the dramatic and often fatal neurological sequelae that follow. It appears that pathophysiologically MBD arises as a consequence of malnutrition. Thus, this case illustrates that treatment can be generalized across various etiologies of malnutrition in MBD, not just alcoholism.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Ethics Approval**

Our institution does not require ethical approval for reporting individual cases or case series.

**Informed Consent**

Verbal informed consent was obtained from a legally authorized representative for anonymized patient information to be published in this article. The patient is deceased, and the patient’s mother provided this consent.

**ORCID iD**

Christopher Banerjee [https://orcid.org/0000-0002-7388-8798](https://orcid.org/0000-0002-7388-8798)

**References**

1. Marchiafava E, Bignami A. Sopra un’alterazione del corpo calloso osservata in soggetti alcoolisti. *Rivista di Patologia Nervosa e Mentale*. 1903;8:544-549.
2. Heinrich A, Runge U, Khaw AV. Clinicoradiologic subtypes of Marchiafava-Bignami disease. *J Neurol*. 2004;251:1050-1059.
3. Berek K, Wagner M, Chemelli AP, Aichner F, Benke T. Hemispheric disconnection in Marchiafava-Bignami disease: clinical, neuropsychological and MRI findings. *J Neurol Sci*. 1994;123:2-5.
4. Victor M, Adams RD, Collins GH. *The Wenicke-Korsakoff Syndrome and Related Disorders Due to Alcoholism and Malnutrition*. Philadelphia, PA: FA Davis; 1989.
5. Fernandes LMP, Bezerra FR, Monteiro MC, et al. Thiamine deficiency, oxidative metabolic pathways and ethanol-induced neurotoxicity: how poor nutrition contributes to the alcoholic syndrome, as Marchiafava-Bignami disease. *Eur J Clin Nutr*. 2017;71:580-586.
6. Hillbom M, Saloheimo P, Fujoka S, Wswolek Z, Juvela S, Leone M. Diagnosis and management of Marchiafava-Bignami disease: a review of CT/MRI confirmed cases. *J Neurol Neurosurg Psychiatry*. 2014;85:168-173.